Will long-term use of Capmatinib cause resistance?

Capmatinib (Capmatinib) is a highly selective MET inhibitor, mainly used to treat patients with MET exon 14 skipping (METex14 skipping mutation) non-small cell lung cancer (NSCLC) patients. As a precision targeted drug, capmatinib has shown significant advantages in improving the treatment response rate and survival of such patients. However, like many targeted therapies, patients may develop drug resistance during long-term use, which is one of the important challenges facing current treatments.

Research has found that the resistance mechanism of capmatinib is complex, mainly including target mutations (such as MET mutations that reduce drug binding ability), activation of alternative pathways (such as KRAS, EGFR and other signaling pathways) and phenotypic transformation (such as epithelial to mesenchymal transition). These changes may cause patients to gradually lose control of their disease after initial apparent benefit. Therefore, drug resistance is not an isolated phenomenon, but a stage of treatment that requires close monitoring and active response.

In order to delay the occurrence of drug resistance, treatment effects should be regularly evaluated and dynamic monitoring at the molecular level should be carried out. Currently, liquid biopsy or repeated tumor tissue biopsy has been gradually adopted clinically to analyze the drug resistance mechanism when the patient's disease progresses, thereby deciding whether to adjust the treatment plan. For example, for MET-dependent resistance mechanisms, other generations of MET inhibitors may be used; if bypass activation is present, combination treatment strategies may be considered.

Overall, capmatinib is effective in initial treatment, but drug resistance may occur with long-term use, requiring adequate preparation and response strategies. Through scientific monitoring methods, in-depth understanding of drug resistance mechanisms and flexible adjustment of treatment plans, patients can maximize the time to benefit and improve the quality of life. For patients receiving capmatinib, long-term management and individualized treatment are key.

Reference materials:https://www.novartis.com/our-products/pipeline/capmatinib